Letter to the Editor

Eric DruytsFaculty of Health Sciences, University of Ottawa Ottawa, ONCanadaCorrespondence[email protected]

Kristian ThorlundDepartment of Clinical Epidemiology and Biostatistics, McMaster University Hamilton, ONCanada;Stanford Prevention Research Centre, Stanford University

Edward J. MillsFaculty of Health Sciences, University of Ottawa Ottawa, ONCanada;Stanford Prevention Research Centre, Stanford University

References

Cure S, Bianic F, Gavart S, et al. Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in previously untreated chronic hepatitis C genotype 1 patients. J Med Econ 2014;17:65-76
PubMedGoogle Scholar
Cure S, Bianic F, Gavart S, et al. Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in treatment-experienced patients. J Med Econ 2014;17:77-87
PubMedGoogle Scholar
Cure S, Diels J, Gavart S, et al. Efficacy of telaprevir and boceprevir in treatment-naïve and treatment experienced genotype 1 chronic hepatitis C patients: an indirect comparison using Bayesian network meta-analysis. Curr Med Res Opin 2012;28:1841-56
PubMed Web of Science ®Google Scholar
Cooper C, Lester R, Thorlund K, et al. Direct-acting antiviral therapies for hepatitis C genotype 1 infection: a multiple treatment comparison meta-analysis. QJM 2013;106:153-63
PubMed Web of Science ®Google Scholar
Cooper C, Druyts E, Thorlund K, et al. Boceprevir and telaprevir for the treatment of chronic hepatitis C genotype 1 infection: an indirect comparison meta-analysis. J Therapeut Clin Risk Manag 2012;5:105-30
Google Scholar
Kieran J, Schmitz S, O’Leary A, et al. The relative efficacy of boceprevir and telaprevir in the treatment of hepatitis C virus genotype 1. Clin Infect Dis 2013;56:228-35
PubMed Web of Science ®Google Scholar
Druyts E, Thorlund K, Humphreys S, et al. Interpreting discordant indirect and multiple treatment comparison meta-analyses: an evaluation of direct acting antivirals for hepatitis C infection. Clin Epidemiol 2013;5:173-83
Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Letter to the Editor

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Letter to the Editor

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date